Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
宜昌東陽光長江藥業股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 01558)

VOLUNTARY ANNOUNCEMENT
ATORVASTATIN CALCIUM TABLETS APPROVED TO LAUNCH

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company is pleased to announce that Atorvastatin Calcium Tablets (10mg, 20mg and 40mg) (the "**Product**") acquired by the Company from Sunshine Lake Pharma Co., Ltd.* (廣東東陽光藥業有限公司) have undergone the assessment and approval process and obtained approval for launch from the China National Medical Products Administration. The marketing authorization holder of the Product is Dongguan Yangzhikang Pharmaceutical Co., Ltd.* (東莞市陽之康醫藥有限責任公司) ("**Yangzhikang**"), a wholly-owned subsidiary of the Company.

Name of the drug (Chinese)	阿托伐他汀鈣片	阿托伐他汀鈣片	阿托伐他汀鈣片
Name of the drug (English)	Atorvastatin Calcium Tablets	Atorvastatin Calcium Tablets	Atorvastatin Calcium Tablets
Form	Tablets	Tablets	Tablets
Specification	10mg	20mg	40mg
Registration category	Type 4 Chemical Drug	Type 4 Chemical Drug	Type 4 Chemical Drug
Handling number	CYHS1900890GUO	CYHS1900891GUO	CYHS1900892GUO
Drug approval number	Guoyaozhunzi (國藥准字) H20213512	Guoyaozhunzi (國藥准字) H20213513	Guoyaozhunzi (國藥准字) H20213514
Certificate number	2021S00681	2021S00682	2021S00683
Marketing authorization holder	Yangzhikang	Yangzhikang	Yangzhikang

Atorvastatin Calcium is suitable for hypercholesterolemia and it can reduce the risk of non-fatal myocardial infarction, the risk of fatal and non-fatal stroke, the risk of revascularization, the risk of hospitalization due to congestive heart failure, and the risk of angina. Atorvastatin Calcium reduces plasma cholesterol and lipoprotein levels by inhibiting the synthesis of HMG-CoA reductase and cholesterol in the liver, and increase the number of LDL receptors on the liver cell surface to enhance the uptake and catabolism of low-density lipoproteins.

Atorvastatin belongs to Class B (乙類品種) under the National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (國家基本醫療保險、工傷保險和生育保險藥品目錄) (2020 edition) and is also an item listed on the National Essential Drugs List (國家基本藥物目錄) (2018 edition). According to data from IQVIA, the sales of Atorvastatin in China in 2020 was approximately USD670 million.

The Product is a generic drug which obtained the approval for launch in China. After obtaining the approval for launch, it has been deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. The Product has high clinical value and favourable market prospects and will become one of the Company's products in the areas of cardiovascular disease treatment after its launch, which will further enrich the Group's product portfolio and will also provide patients with a choice of medication with high quality and fair price.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
28 June 2021

As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive directors.

* *For identification purposes only*